ProQR cash rises to about €103.0M in Q3 2026 interim accounts
The Dutch RNA therapeutics company reports higher cash and equity in unaudited IFRS interim statements that refer to a June public offering and its Eli Lilly collaboration.
ProQR Therapeutics has furnished unaudited interim condensed financial statements, prepared under IFRS, for the period ended 30 September 2026. The company reports cash and cash equivalents of about €103.0M, up from €92.4M at the end of 2025.
Equity increased to €68.2M. The notes to the accounts refer to an underwritten public offering in June 2026 and to at-market sales arranged with Cantor. The company's headline links the stronger balance sheet to the June offering.
The statements also refer to ProQR's collaboration with Eli Lilly. Deferred income fell over the period.
The summary available to VigiEye does not include a full income statement, cash-burn figures or any pipeline or regulatory updates, so this report is limited to the balance-sheet items above.
Why it matters
- Partners and observers of ProQR can use the higher cash position and equity as a reference point when assessing the company's funding position, based on the reported figures.
- The filing contains no regulatory or pharmacovigilance milestones in the material reviewed; any programme news would have to come from separate company disclosures.
- The Lilly collaboration is still referenced in the notes, and the decline in deferred income is a line item to watch in later filings.
Company's press release (SEC filing): ProQR Therapeutics N.V. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
